Lenalidomide Eugia (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4 E3 ubiquitin ligase complex, altering its substrate specificity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic effects, enhanced immune activation, and programmed cell death of malignant plasma cells and dysplastic clones.

The specific dose of Lenalidomide Eugia is determined by the prescribing clinician based on the patient’s disease type, stage, renal function, and overall health. Only a qualified healthcare professional can set the appropriate regimen for each individual.

Lenalidomide is classified as contraindicated in pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while taking the medication. Consultation with a healthcare provider is essential for risk assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

The primary alternative to Lenalidomide in these indications is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, and provides stronger anti‑angiogenic activity, though both require careful monitoring for thrombotic events.

Lenalidomide Eugia should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions preserves the tablet’s stability and potency throughout its shelf life.

The medication is taken orally, usually with a glass of water. It may be administered with or without food, depending on the prescriber’s instructions. Patients should follow the exact dosing schedule provided by their healthcare professional.

Serious risks include venous thromboembolism, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic toxicity. Patients should be educated to report signs of clot formation, unusual rashes, or liver‑related symptoms promptly to their physician.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to the drug, and patients with uncontrolled active infections. It should also be used with caution in those with severe renal impairment or a history of thrombotic events, after thorough clinical evaluation.